



***Aloysia citrodora* extract as a chemopreventive agent against HPV16-induced lesions: findings from K14-HPV16 mice**

Beatriz Medeiros-Fonseca^{1,2,3} , Ana I. Faustino-Rocha^{1,2,4,5} , Jéssica Silva^{1,2} , Mónica G. Silva⁶ , Maria João Pires^{1,2,7} , Maria João Neuparth^{8,9} , Helena Vala^{1,2,10,11} , Cármen Vasconcelos-Nóbrega^{1,2,10,11} , Maria I. Dias^{12,13} , Lillian Barros^{12,13} , Lio Gonçalves^{14,15} , Isabel Gaivão^{16,17} , Margarida M. S. M. Bastos^{18,19} , Luís Félix^{1,2} , Carlos Venâncio^{1,2,17,20} , Rui Medeiros^{3,21,22,23,24} , Rui M. Gil da Costa^{1,2,3,18,19,25} , Paula A. Oliveira^{1,2,7*} 

¹Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal

²Institute for Innovation, Capacity Building and Sustainability of Agri-food Production (Inov4Agro), University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal

³Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal

⁴Department of Zootechnics, School of Sciences and Technology, University of Évora, 7000-812 Évora, Portugal

⁵Comprehensive Health Research Center (CHRC), University of Évora, 7000-812 Évora, Portugal

⁶Centro de Química de Vila Real (CQVR), Chemistry Department, University of Trás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal

⁷Department of Veterinary Sciences, University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal

⁸Laboratory for Integrative and Translational Research in Population Health (ITR), Research Center in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sports, University of Porto, 4200-450 Porto, Portugal

⁹UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal

¹⁰CERNAS-IPV Research Centre, Polytechnique Institute of Viseu, 3504-510 Viseu, Portugal

¹¹Polytechnique Institute of Viseu, Agrarian School of Viseu, Campus Politécnico, 3504-510 Viseu, Portugal

¹²The Mountain Research Center of the Polytechnic Institute of Bragança (CIMO), Campus Santa Apolónia, 5300-253 Bragança, Portugal

¹³Associate Laboratory for Sustainability and Technology in Mountain Regions (SusTEC) of the Polytechnic Institute of Bragança, Campus Santa Apolónia, 5300-253 Bragança, Portugal

¹⁴Department of Engineering, University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal

¹⁵Institute for Systems and Computer Engineering, Technology and Science (INESC-TEC), 4200-465 Porto, Portugal

¹⁶Department of Genetics and Biotechnology, University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal

¹⁷Animal and Veterinary Research Centre (CECAV), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal

¹⁸Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), Faculty of Engineering of the University of Porto (FEUP), 4200-465 Porto, Portugal

¹⁹Associate Laboratory in Chemical Engineering (ALiCE), Faculty of Engineering of the University of Porto (FEUP), 4200-465 Porto, Portugal

²⁰Department of Animal Science, School of Agrarian and Veterinary Sciences (ECAV), University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal

²¹Research Department of the Portuguese League against Cancer — Regional Nucleus of the North (LPCC-NRN), 4200-177 Porto, Portugal

²²Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal

²³Virology Service, Portuguese Institute of Oncology (IPO), 4200-072 Porto, Portugal

²⁴Biomedical Research Center (CEBIMED), Faculty of Health Sciences of Fernando Pessoa University (UFP), 4249-004 Porto, Portugal

²⁵Postgraduate Programme in Adult Health (PPGSAD), Department of Morphology, Federal University of Maranhão (UFMA), São Luís 65020-070, Brazil

© The Author(s) 2024. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



***Correspondence:** Paula A. Oliveira, Centre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes e Alto Douro (UTAD), 5000-801 Vila Real, Portugal. pamo@utad.pt

Academic Editor: Andrea Giannini, Sapienza University of Rome, Italy

Received: February 1, 2024 **Accepted:** April 26, 2024 **Published:** June 18, 2024

Cite this article: Medeiros-Fonseca B, Faustino-Rocha AI, Silva J, Silva MG, Pires MJ, Neuparth MJ, et al. *Aloysia citrodora* extract as a chemopreventive agent against HPV16-induced lesions: findings from K14-HPV16 mice. *Explor Med.* 2024;5:416–33. <https://doi.org/10.37349/emed.2024.00228>

Abstract

Aim: *Aloysia citrodora* has a long history of traditional use in treating various ailments. This study evaluated the *in vivo* chemopreventive efficacy and systemic toxicity of an extract of *A. citrodora* in a transgenic mouse model of HPV16 (human papillomavirus type 16)-induced cancer.

Methods: The experiment involved six groups ($n = 5$): group 1 (G1, *wild-type* (WT), water), group 2 (G2, HPV, water), group 3 (G3, WT, 0.013 g/mL), group 4 (G4, HPV, 0.006 g/mL), group 5 (G5, HPV, 0.008 g/mL), and group 6 (G6, HPV, 0.013 g/mL). Throughout the assay, humane endpoints, body weight, food, and water consumption were recorded weekly. The internal organs and skin of the mice were collected for analysis after they were sacrificed. Toxicological parameters that were studied included hematological and biochemical blood markers, splenic and hepatic histology, and hepatic oxidative stress.

Results: *A. citrodora* extract seems to reduce the incidence of dysplastic and *in situ* carcinoma skin lesions induced by HPV16 in this model, suggesting that dietary supplementation with concentrations of 0.008 g/mL and 0.013 g/mL may have beneficial chemopreventive effects.

Conclusions: The extract did not induce any concentration-dependent toxicological effects on any of the parameters included in the study, indicating a favorable toxicological profile under these experimental conditions.

Keywords

Aloysia citrodora, cancer, HPV16, natural extract, mouse model

Introduction

Aloysia citrodora, commonly known as lemon verbena, is a medicinal plant that is native to South America, North Africa, and Southern Europe. It is commonly used to treat various symptoms such as insomnia, diarrhea, rheumatism, and flatulence [1]. The essential oil extracted from the dried leaves of *A. citrodora* is effective in treating problems such as anxiety, stress, insomnia, some types of depression, nervous fatigue, multiple sclerosis, tachycardia, rheumatism, psoriasis, anorexia, dyspepsia, and asthma [2, 3]. The biological activities associated with this plant are diverse and related to its chemical composition. Therefore, differences in its applicability can be explained by variations in chemical composition [4]. It should be noted that the essential oil of *A. citrodora* has an antitumor effect, demonstrated by Salama et al. [5], who showed that it blocked the growth of melanoma cells *in vitro* and impaired the growth of primary tumor cells *in vivo*. Other studies revealed that *A. citrodora* possesses antiviral, antioxidant, anti-inflammatory and immunomodulatory properties [6, 7]. Given these positive results, an *in vivo* study would be useful to further advance the preclinical study of *A. citrodora* extracts as a potential cancer chemopreventive agent. Thus, this work aims to investigate the *in vivo* effects of an aqueous extract of *A. citrodora* in a transgenic mouse model of cancer induced by high-risk human papillomavirus type 16 (HPV16) [8]. HPV stands as the foremost cause of cervical dysplasia and cervical cancer. The enduring presence of HPV is recognized as a primary risk factor for the emergence of cervical lesions and their recurrence after treatment [9]. The study by Bogani et al. [10], states that persistence of HPV for up to one year increased the risk of recurrence of grade 2 invasive carcinoma, while persistence after the first year did not appear to be a risk factor. High viral load and persistence of HPV are significant factors in the development of primary and recurrent

cervical dysplasia. Patients with HPV16/18 and other high-risk HPV types showed different rates of persistence at various time intervals, influencing the risk of recurrence. Risk factors such as tobacco use, and epigenetic interactions play a role in HPV persistence and patient outcomes [10]. It is important to highlight the importance of adopting vaccination against HPV [11]. A study carried out by Bogani et al. [12], reports that individuals who have been vaccinated have a slightly lower risk of recurrence than individuals who have not been vaccinated. The K14-HPV16 model has previously been used to investigate the effects of natural compounds such as *Laurus nobilis* (laurel) [13], vegetable toxins like ptaquiloside from *Pteridium* spp. (bracken) [14], and dietary polyphenols such as curcumin and rutin [15]. In previous studies, K14-HPV16 mice showed a strong tendency to develop excessive hepatic and splenic inflammation, rendering them a suitable model for studying the effects of *A. citrodora* extract. The present study aimed to evaluate the *in vivo* chemopreventive efficacy and systemic toxicity of an *A. citrodora* extract in an HPV16-transgenic mouse model of cancer. The extract exhibited a tendency to decrease the incidence of HPV16-induced lesions and displayed a favorable toxicological profile.

Materials and methods

Sample preparation

A. citrodora extract was obtained from a Portuguese company (Celeiro®, batch number 03LUC1099J211S) collected in May 2021 and prepared through infusion extraction. Three concentrations of the *A. citrodora* extract (0.006 g/mL, 0.008 g/mL, and 0.013 g/mL) were prepared in tap water heated to 90°C using a French press. The resulting mixture was filtered and allowed to cool at room temperature (20–25°C) for 20 min before being given to animals as drinking water every two days.

Analysis of phenolic compounds

The LC-DAD-ESI/MSⁿ method (Dionex UltiMate 3000 UHPLC, Thermo Scientific, San Jose, CA, USA) was used to determine the phenolic profile. The compounds were separated and identified following the procedure described by Bessada et al. [16]. The extracts obtained were redissolved in ethanol:water (80:20, v/v) mixture at a concentration of 50 mg/mL. A double online detection was performed using a DAD with preferred wavelengths of 280, 330, and 370 nm, and a mass spectrometer (MS). The MS detection was carried out in negative mode, using a Linear Ion Trap LTQ XL MS (Finnigan, Thermo Fisher Scientific, San Jose, CA, USA) equipped with an ESI source. Phenolic compounds were identified based on their chromatographic behaviour, and UV-vis and mass spectra, by comparison with standard compounds, when available, and data reported in the literature, resulting in tentative identification. The Xcalibur® data system (Finnigan, Thermo Fisher Scientific, San Jose, CA, USA) was used for data acquisition. For quantitative analysis, a calibration curve was constructed for each available phenolic standard based on the UV-vis signal: apigenin-7-*O*-glucoside ($y = 10,683x - 45,794$; $R^2 = 0.996$); *p*-coumaric acid ($y = 301,950x + 6,966.7$; $R^2 = 0.9999$); quercetin-3-*O*-glucoside ($y = 34,843x - 160,173$; $R^2 = 0.9998$); and verbascoside ($y = 124,233x - 18,873$; $R^2 = 0.9999$). For the identification of phenolic compounds without a commercial standard, quantification was performed using the calibration curve of the most similar available standard. The results were expressed as mg/g of extract.

Mice

Thirty female *Mus musculus* of the FVB/n strain were used in this study: twenty transgenic (HPV+) and ten *wild-type* (HPV-, WT) mice aged 16–24 weeks. This age group is known to develop dysplastic skin lesions that later progress into squamous cell carcinomas [8]. Female mice were selected due to their ease of maintenance, as males are known to be highly aggressive and territorial [17]. The mouse strain used in this study was generously donated by Doctors Jeffrey Arbeit and Douglas Hanahan from the University of California, through the National Cancer Institute Mouse Repository (USA). The animals were genotyped using a polymerase chain reaction technique, as previously described [18].

Experimental procedures

This experimental work was conducted at the animal facility of the University of Trás-os-Montes e Alto Douro (UTAD) with the authorization of the Ethics Committee (approval no. 852-e-CITAB-2020_A_1-e- 122 CITAB-2021) and the Portuguese Veterinary Directorate (approval no. 014139). During the experimental period, the animals were fed a standard diet (4RF21 GLP, Mucedola, Italy) *ad libitum* and drank tap water. The environmental temperature was maintained at 21–25°C, with a light-dark cycle of 12 hours of light and 12 hours of dark, and relative humidity of 40–60%. The experimental study involved six groups: group 1 (G1, WT, water, $n = 5$), group 2 (G2, HPV, water, $n = 5$), group 3 (G3, WT, 0.013 g/mL, $n = 5$), group 4 (G4, HPV, 0.006 g/mL, $n = 5$), group 5 (G5, HPV16, 0.008 g/mL, $n = 5$) and group 6 (G6, HPV16, 0.013 g/mL, $n = 5$). Following the guidelines of Russell and Burch regarding the use of animals for experimental purposes, particularly the 3Rs (reduce, refinement, and replacement), and aiming to minimize the number of animals used in this experiment without compromising its scientific quality, we administered the highest concentration to healthy animals [19]. We assumed that if toxicity were induced by *A. citrodora*, it would likely occur at the highest concentration. The humane endpoints were evaluated on a weekly basis, including body mass, hair appearance, eyes, ears and whiskers, mental status, and presence of papilloma, among other factors, as described by Silva-Reis et al., in 2021 [20]. Animals that reached a score of 4 or higher were euthanized before completing the experimental assay [21]. Throughout the experiment, the animals' weight, water intake and food consumption were recorded on a weekly basis. At the end of the experimental trial, the animals were sacrificed using a 10:1 ratio of ketamine (100 mg/kg) and xylazine (10 mg/kg), followed by exsanguination via cardiac puncture, in accordance with the Federation of European Laboratory Animal Science Association guidelines [22]. Blood was collected for biochemical and hematological analysis, as well as for the comet assay. The heart, lungs, liver, spleen, and kidneys were collected for histological analysis and to assess oxidative stress.

Microhematocrit and biochemical parameters

Blood was collected into lithium heparin tubes and centrifuged at 20,000 rpm for 15 min. The plasma supernatant was then stored at –80°C. For microhematocrit evaluation, blood was centrifuged in capillary tubes at 12,000 rpm for 5 min. Biochemical parameters were studied using previously frozen plasma to determine concentrations of albumin, total protein, creatinine, urea, and alanine aminotransferase in an autoanalyzer (PRESTIGE 24I, PZ CORMAY). To measure blood glucose levels, the animals fasted for 12 hours before a blood sample was taken and analyzed using a GlucoMen Areo 2K glucometer with Glucomen Areo Sensor brand strips.

Comet assay

The alkaline comet assay ($\text{pH} > 13$) was performed using previously established methods [23, 24]. Normal melting point agarose (1%) was used to cover the slides. Four slides were prepared for each animal, with two slides used for the assay with the enzyme and the other two for the assay without the enzyme. To create a cell suspension, 20 μL of blood was diluted in 200 μL of ice-cold phosphate-buffered saline (1 $\times$) in a 0.5 mL microtube. Sixty μL of cell suspension were mixed with 600 μL of low melting point agarose (1%) and placed on four pre-coated slides (two replicates *per* slide), with 70 μL gels. The slides were then immersed in a lysis solution and rinsed in a washing buffer three times. To measure oxidatively damaged deoxyribonucleic acid (DNA) precisely, namely 8-oxoguanines and other altered purines, two slides *per* animal were incubated with formamidopyrimidine DNA glycosylase (FPG) for 30 min. FPG is a DNA lesion-specific enzyme that converts oxidized purines into DNA single-strand breaks. The enzyme was donated by Professor Andrew Collins from the University of Oslo, Norway. To allow DNA unwinding, slides with and without FPG treatment were gently immersed in a freshly prepared alkaline electrophoresis solution. The cells underwent electrophoresis in the same solution for 20 min at 25 V and a current of 300 mA. Subsequently, the cells were immersed in phosphate-buffered saline, followed by distilled water, dehydrated, and air-dried. To enable visual scoring, DNA was stained with a 1 $\mu\text{g/mL}$ solution of 4,6-diamidino-2-phenylindole (Sigma-Aldrich Chemical Company, Spain) and observed using an Olympus BX41 fluorescence microscope at 400 $\times$. The nuclei were visually classified into five classes ranging from 0 (no

tail) to 4 (almost all DNA in the tail) [25]. One hundred nuclei were observed *per* replicate (200 *per* case) and the genetic damage index (GDI) was expressed on an arbitrary scale of 0 to 400 (arbitrary units, AU) using the following formula:

$$\text{GDI} = (n \text{ class } 0 \times 0) + (n \text{ class } 1 \times 1) + (n \text{ class } 2 \times 2) + (n \text{ class } 3 \times 3) + (n \text{ class } 4 \times 4)$$

Histology

The tissue samples were fixed in 10% neutral buffered formalin and processed for histological analysis. They were then stained with hematoxylin and eosin. All slides were examined under light microscopy using a Zeiss Axioplan 2 microscope. Image processing was performed using the LAS Advanced Analysis Software Bundle (No: 12730448). Lesions found in the ear pavilion and chest skin were classified as epidermal hyperplasia, dysplasia, papilloma, or carcinoma, as previously described [15]. The lung lesions were classified as mononuclear inflammation, atelectasis, emphysema, bleeding, airway desquamation, congestion, hyalinization, and hemorrhage. The liver lesions were classified as vacuolar degeneration, inflammation, and congestion, while the spleen showed hyperplasia and congestion [13, 15]. The heart lesions were classified as myofiber hyalinization, congestion, hemorrhage, and vascular ectasia. The kidney lesions were classified as inflammatory infiltrate, hydronephrosis, congestion, hyperemia, and vascular ectasia, as previously described [15, 26–29].

Hepatic and renal oxidative stress

Liver and kidney samples were collected and stored at -80°C . The samples were homogenized using TissueLyser II QIAGEN in a cold buffer solution (0.32 mM sucrose, 20 mM HEPES, 1 mM MgCl_2 , and 0.5 mM phenylmethyl sulfonyl fluoride, pH 7.4). The homogenate was then centrifuged at $15,000 \times g$ for 20 min at 4°C (Prism R, Labnet International, USA), and the resulting supernatants were collected for further analysis. Superoxide dismutase (Cu/Zn-SOD) activity was measured by reducing nitroblue tetrazolium generated by the xanthine/xanthine oxidase system at 560 nm [30]. A standard curve was created using SOD (Sigma, S7446) from bovine erythrocytes ($0\text{--}600 \text{ U}\cdot\text{mL}^{-1}$). Catalase (CAT) activity was determined at 240 nm using a previously published method [31] and calculated using bovine CAT (Sigma, C40) as a standard ($0\text{--}696 \text{ U}\cdot\text{mL}^{-1}$). Glutathione peroxidase (GPx) activity was determined at 340 nm [32] using an extinction coefficient of $6.22 \text{ mM}^{-1}\cdot\text{cm}^{-1}$. Glutathione reductase (GR) activity was determined by measuring the increase in absorbance of NADPH at 340 nm [33] using a molar extinction coefficient of $6.22 \text{ mM}^{-1}\cdot\text{cm}^{-1}$. Glutathione *S*-Transferase (GST) activity was determined by measuring the increase in absorbance at 340 nm resulting from the conjugation of the thiol group of glutathione to the 1-Chloro-2,4-dinitrobenzene (CDNB) substrate [34], using a molar extinction coefficient of $9.60 \text{ mM}^{-1}\cdot\text{cm}^{-1}$. The levels of glutathione were determined by measuring its reduced (GSH) and oxidized states (GSSG) using the fluorochrome orthophthalaldehyde with excitation and emission wavelengths of 320 nm and 420 nm, respectively [35]. Concentrations were estimated based on standard curves of GSH (Sigma, G4251) and GSSG (Sigma, G4626) ($0\text{--}1 \text{ mM}$). The oxidative stress index (OSI) was calculated as the ratio between GSH and GSSG. The synthesis of reactive oxygen species (ROS) was estimated using the fluorescent probe 2,7-dichlorofluorescein diacetate, according to a previously published method [36], with excitation and emission wavelengths of 485 nm and 530 nm, respectively. A standard curve was constructed using DCF (Sigma, 35848) ($0\text{--}500 \mu\text{M}$). The levels of malondialdehyde (MDA), an indicator of lipid peroxidation (LPO), were measured at 535 nm (MDA-thiobarbituric acid adducts) and 600 nm (nonspecific adducts) wavelengths using the thiobarbituric acid method described elsewhere [37]. MDA levels (Sigma, 31640) were estimated based on a standard curve ($0\text{--}1,000 \mu\text{M}$) of malonaldehyde bis(dimethyl acetal). Carbonyls (CO) were estimated at 450 nm using the methodology described by Mesquita et al. [38].

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, NY, USA) and GraphPad Prism version 9. The normal distribution was analyzed considering the Shapiro-Wilks test and the analysis of variances considering the Levene test. For results with normal distribution, we performed an ANOVA followed by the Bonferroni test. For results without normal distribution, we use

non-parametric tests such as the Kruskal-Wallis test. We considered values of $P < 0.05$ to be statistically significant. The parameters that apply this rule are body weight, food and drink consumption, organ mass, humane endpoints, hematologic, and oxidative stress parameters. A Chi-square test was performed to analyze the association between histological lesions and groups.

- Humane endpoints = (sum score per animal) / (number of animals *per cage*)
- Weight gain = (final weight – initial weight) / (initial weight) × 100 (%)
- Average daily consumption (water/food) *per animal per day* = [(initial mass) – (final mass)] / (number of days between weighing's) × (number of animals *per cage*) (g)
- Relative weight of organs = (organ weight) / (body weight) (g)

Results

Phenolic characterization of *A. citrodora* extract

The phenolic profile of *A. citrodora* extract was analyzed and several compounds were identified and quantified (Table 1). Most of the identified molecules were previously described in the literature, as mentioned in Table 1. Verbascoside was the main compound present, followed by luteolin 7-*O*-diglucuronide.

Table 1. Retention time (Rt) (min), maximum absorption in the visible region (λ_{max}) (nm), deprotonated ion ([M-H]) (m/z), mass fragmentation (MS^2) (m/z), tentative identification, and quantification (mg/g extract) of the phenolic compounds found (mean ± standard deviation)

Peak	Rt (min)	λ_{max} (nm)	[M-H] (m/z)	MS^2 (m/z)	Tentative identification	Quantification (mg/g extract)	Reference used for identification
1	4.35	280	461	315(8), 135(28)	Verbascoside	4.35 ± 0.27	[29]
2	5.02	328	487	179(100)	Cistanoside F	3.13 ± 0.09	[29]
3	5.64	358	389	371(23), 345(100), 209(51), 179(10), 121(12)	Theveside	2.43 ± 0.1	[29]
7	11.51	330	639	621(12), 459(23)	β -hydroxy-verbascoside/ β -hydroxy-isoverbascoside	3.17 ± 0.04	[29]
8	11.97	330	639	621(15), 459(22)	β -hydroxy-verbascoside/ β -hydroxy-isoverbascoside	3.58 ± 0.17	[29]
9	12.69	344	637	351(100), 285(73)	Luteolin 7- <i>O</i> -diglucuronide	17.02 ± 0.06	[30]
10	14.99	314	163	119(100)	<i>p</i> -Coumaric acid	2.69 ± 0.05	[30]
11	15.91	335	621	351(100), 269(24)	Apigenin 7- <i>O</i> -diglucuronide	8.29 ± 0.11	[30]
12	16.66	331	623	461(21), 315(7)	Verbascoside	115.07 ± 0.21	[30]
13	17.99	354	651	351(100), 299(4)	Chrysoeriol 7- <i>O</i> -diglucuronide	3.53 ± 0.03	[30]
14	18.69	331	623	461(19), 315(14)	Isoverbascoside	2.62 ± 0.01	[30]
15	19.23	331	623	461(16), 315(5)	Forsythoside	8.23 ± 0.36	[30]
16	21.23	350	491	315(100), 300(24)	Isorhamnetin 3- <i>O</i> -glucuronide	0.76 ± 0.01	[30]
17	22.56	332	637	491(6), 461(63), 315(14)	Eukovoside	2.06 ± 0.01	[30]
18	22.48	332	651	505(5), 475(27)	Martinoside	2.36 ± 0.06	[30]
Total caffeoyl phenylethanoid glycoside (mg/g extract)						147.00 ± 0.15	
Total phenolic acids (mg/g extract)						2.69 ± 0.05	
Total flavonoids (mg/g extract)						29.6 ± 0.15	
Total phenolic compounds (mg/g extract)						179.29 ± 0.35	

Rt: retention time; λ_{max} : maximum absorption in the visible region; [M-H]: deprotonated ion; MS^2 : mass fragmentation

General findings, food and drink intake, and organs' weight

No behavioral or phenotypic changes were observed throughout the trial. Additionally, no mortality occurred during the experimental period. Regarding humane endpoints, statistically significant differences were found between group 2 (HPV, water) and group 4 (HPV, 0.006 g/mL), as well as between group 4 (HPV, 0.006 g/mL) and group 5 (HPV, 0.008 g/mL) ($P < 0.05$) (Table 2). All animals gained weight during

the experiment. No animal reached the threshold for euthanasia (score 4). The body weight increased throughout the experimental assay, but there were no statistically significant differences between groups. In terms of weight gain, there were also no statistically significant differences between groups (Table 2). Regarding to food and water consumption *per* animal, HPV16 animals exhibited higher consumption levels (Table 2). Finally, although there were no statistically significant differences between groups, the weight of all organs was higher in the HPV16 groups compared to the WT groups (Table 3).

Table 2. Humane endpoints, body weight (g) at the beginning and at the end of the study, weight gain (%), average daily consumption of the food (g) and drink (mL) during the experimental trial (mean $\pm$ standard deviation)

Group	Humane endpoints	Body weight		Weight gain (%)	Average daily consumption	
		Initial (g)	Final (g)		Food (g)	Drink (mL)
G1 WT water	0.08 $\pm$ 0.18	29.65 $\pm$ 1.61	31.54 $\pm$ 3.29	6.24 $\pm$ 7.18	4.02	5.07
G2 HPV water	0.36 $\pm$ 0.41 ¹	27.91 $\pm$ 3.19	28.69 $\pm$ 3.84	2.60 $\pm$ 3.65	4.24	6.46
G3 WT 0.013 g/mL	0.24 $\pm$ 0.22	25.24 $\pm$ 1.27	26.72 $\pm$ 0.95	5.92 $\pm$ 2.19	4.26	5.18
G4 HPV 0.006 g/mL	1.04 $\pm$ 0.09 ²	23.83 $\pm$ 1.98	25.07 $\pm$ 2.00	3.12 $\pm$ 4.72	3.50	6.60
G5 HPV 0.008 g/mL	0.36 $\pm$ 0.26	28.21 $\pm$ 4.73	28.99 $\pm$ 4.24	5.38 $\pm$ 6.74	4.29	8.01
G6 HPV 0.013 g/mL	0.80 $\pm$ 0.40	24.44 $\pm$ 3.62	26.68 $\pm$ 3.89	9.24 $\pm$ 3.28	4.07	7.69

¹ Statistically different from G4 ($P < 0.05$). ² Statistically different from G5 ($P < 0.05$). G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL

Table 3. Relative organs' weight in milligrams (mean $\pm$ standard deviation)

Organs	G1 WT water	G2 HPV water	G3 WT 0.013 g/mL	G4 HPV 0.006 g/mL	G5 HPV 0.008 g/mL	G6 HPV 0.013 g/mL
Heart	3.8 $\pm$ 0.3	4.2 $\pm$ 0.5	4.0 $\pm$ 0.5	4.7 $\pm$ 0.3	4.3 $\pm$ 0.2	4.3 $\pm$ 0.7
Lung	6.0 $\pm$ 0.3	6.2 $\pm$ 1.3	6.0 $\pm$ 0.5	6.7 $\pm$ 0.5	6.5 $\pm$ 0.6	6.5 $\pm$ 0.6
Spleen	3.4 $\pm$ 1.3	4.5 $\pm$ 1.0	4.2 $\pm$ 1.0	5.2 $\pm$ 0.5	4.5 $\pm$ 1.0	5.0 $\pm$ 1.6
Liver	41.6 $\pm$ 2.8	47.1 $\pm$ 2.3	42.3 $\pm$ 3.0	44.1 $\pm$ 2.9	42.7 $\pm$ 5.0	44.6 $\pm$ 5.5
Right kidney	5.4 $\pm$ 0.5	6.1 $\pm$ 0.4	5.5 $\pm$ 0.9	6.1 $\pm$ 0.5	6.2 $\pm$ 0.6	5.9 $\pm$ 0.6
Left kidney	4.9 $\pm$ 0.5	5.8 $\pm$ 0.4	5.5 $\pm$ 0.5	5.9 $\pm$ 0.5	6.0 $\pm$ 0.5	5.6 $\pm$ 0.7

G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL

Microhematocrit and biochemical parameters

No concentration-dependent changes were observed for any parameters (Table 4). However, statistically significant differences were found between groups in terms of glucose levels: G2 (HPV, water) showed a larger increase compared to G4 (HPV, 0.006 g/mL) and G6 (HPV, 0.013 g/mL). The same trend was observed for the parameter total protein, which showed a statistically significant difference between G3 (WT, 0.013 g/mL) and G6 (HPV, 0.013 g/mL), with G6 showing a higher value.

Comet assay

The comet assay did not reveal any significant genotoxic blood damage in association with the HPV16 transgenes. There was a tendency to increase the total GDI in HPV animals that ingested the extract when compared to their control. The same applies to oxidation damage revealed by GDI_{fp} (Figure 1), but these observations did not reach the level of statistical significance ($P > 0.05$).

Table 4. Microhematocrit, glucose, and biochemical parameters (mean $\pm$ standard deviation)

Parameters	G1 WT water	G2 HPV water	G3 WT 0.013 g/mL	G4 HPV 0.006 g/mL	G5 HPV 0.008 g/mL	G6 HPV 0.013 g/mL
Microhematocrit (%)	46.84 $\pm$ 2.30	47.70 $\pm$ 1.54	45.52 $\pm$ 1.32	46.62 $\pm$ 2.27	44.68 $\pm$ 1.34	47.38 $\pm$ 2.10
Glucose (mg/dL)	152.60 $\pm$ 12.54	174.72 $\pm$ 20.19 ^{1,2}	144.40 $\pm$ 30.88	109.40 $\pm$ 26.25	137.00 $\pm$ 38.61	94.20 $\pm$ 38.79
Albumin (g/L)	3.19 $\pm$ 0.87	2.92 $\pm$ 0.13	3.01 $\pm$ 0.51	3.16 $\pm$ 0.18	2.91 $\pm$ 0.18	3.37 $\pm$ 0.40
Total proteins (g/L)	44.64 $\pm$ 4.36	44.79 $\pm$ 4.85	41.13 $\pm$ 6.45 ¹	49.48 $\pm$ 3.33	46.75 $\pm$ 2.98	52.89 $\pm$ 6.04
Creatinine (mg/dL)	0.28 $\pm$ 0.43	0.54 $\pm$ 0.41	0.25 $\pm$ 0.38	0.33 $\pm$ 0.67	0.46 $\pm$ 0.49	0.46 $\pm$ 0.90
Urea (mg/dL)	62.66 $\pm$ 8.02	63.58 $\pm$ 15.99	78.80 $\pm$ 4.13	66.18 $\pm$ 7.35	54.42 $\pm$ 10.72	59.18 $\pm$ 13.42
ALT (U/L)	65.36 $\pm$ 17.69	203.16 $\pm$ 281.33	88.70 $\pm$ 27.69	65.50 $\pm$ 22.37	78.63 $\pm$ 13.05	154.35 $\pm$ 136.12

¹ Statistically different from G6 ($P < 0.05$). ² Statistically different from G4 ($P < 0.05$). G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL. ALT: alanine aminotransferase




Figure 1. Mean values of the genetic damage index (GDI) in the blood, measured by the alkaline comet assay (mean $\pm$ standard deviation). Treatment without formamidopyrimidine DNA glycosylase (Fpg) treatment (GDI) is shown in white and treatment with Fpg (GDI_{Fpg}) is shown in black. G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL.

Histology

HPV-induced lesions

Table 5 and Figure 2 summarize the results of the histology of the ear skin and chest skin. As expected, cutaneous lesions were exclusively observed in the HPV groups on the ear pavilion skin, while all animals in the two WT groups displayed normal (0%) auricular skin, indicating that the extract did not cause any harm to the ear skin. Lesions were recorded in all HPV groups. The number of animals with dysplasia was statistically lower in G1 (WT, water) than in G2 (HPV, water) ($P < 0.05$). Regarding the congestion parameter, G1 (WT, water) showed a statistically significant lower incidence than G2 (HPV, water) ($P < 0.05$), and G3 (WT, 0.013 g/mL) showed a statistically lower incidence than G6 (HPV, 0.013 g/mL) ($P < 0.05$). The number of animals with carcinoma *in situ* was statistically lower in G1 (WT, water) than in G2 (HPV, water) ($P < 0.05$). Regarding chest skin histology, the WT animals [G1 (WT, water) and G3 (WT, 0.013 g/mL)] exhibited normal chest skin (100%). This confirms that the extract did not cause any histological skin lesions in WT animals. G3 (WT, 0.013 g/mL) showed lower frequencies of sebaceous and epidermal hyperplasia than G6 (HPV, 0.013 g/mL) ($P < 0.05$).

Table 5. Number of animals (%) with histological cutaneous lesions in all experimental groups

Histological cutaneous lesions		G1 WT water	G2 HPV water	G3 WT 0.013 g/mL	G4 HPV 0.006 g/mL	G5 HPV 0.008 g/mL	G6 HPV 0.013 g/mL
Ear pavilion lesions							
Dysplasia		0(0%) ¹	5(100%)	0(0%)	5(100%)	4(80%)	4(80%)
Papilloma		0(0%)	3(50%)	0(0%)	2(40%)	0(0%)	1(20%)
Sebaceous hyperplasia		0(0%)	4(80%)	0(0%)	3(60%)	4(80%)	1(20%)
Inflammatory infiltrate		0(0%) ¹	5(100%)	0(0%) ²	5(100%)	5(100%)	5(100%)
Congestion		0(0%) ¹	5(100%)	0(0%) ²	0(0%)	0(0%)	1(20%)
Hyperplasia							
Simple	Focal	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(20%)
	Diffuse	0(0%)	0(0%)	0(0%)	0(0%)	1(20%)	0(0%)
Papillary	Focal	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Diffuse	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Papillomatosis	Focal	0(0%)	2(40%)	0(0%)	3(60%)	4(80%)	2(40%)
	Diffuse	0(0%)	2(40%)	0(0%)	1(20%)	0(0%)	0(0%)
Carcinoma							
Carcinoma <i>in situ</i>		0(0%)	1(20%)	0(0%)	0(0%)	0(0%)	0(0%)
Small invasive carcinoma		0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Invasive carcinoma		0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Chest skin lesions							
Dysplasia		0(0%) ¹	5(100%)	0(0%)	5(100%)	4(80%)	4(80%)
Sebaceous hyperplasia		0(0%) ¹	5(100%)	0(0%) ²	5(100%)	4(80%)	5(100%)
Inflammatory infiltrate		0(0%)	4(80%)	0(0%)	4(80%)	3(50%)	3(50%)
Simple	Simple	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Diffuse	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	1(20%)
Papillary	Diffuse	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Focal	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Papillomatosis	Diffuse	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Focal	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Papiloma	Inverted papiloma	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Exophytic papiloma	0(0%)	2(40%)	0(0%)	1(20%)	1(20%)	1(20%)
Carcinoma	Carcinoma <i>in situ</i>	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Small invasive carcinoma	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Invasive carcinoma	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)

¹ Significantly different from the G2 ($P < 0.05$). ² Significantly different from the G6 ($P < 0.05$). G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL

Histological analysis of internal organs

The results of the histology of lungs, liver, spleen, and kidney are summarized in Table 6 and Figure 3. Statistically significant differences were observed in the incidence of atelectasis in the lungs, being higher in G2 (HPV, water) when compared with G1 (WT, water) ($P < 0.05$). No statistically significant differences were observed in the remaining selected organs.

Liver and kidney oxidative stress

In terms of the analysis of hepatic oxidative stress, statistically higher levels of ROS were observed in G2 (HPV, water) when compared to G6 (HPV, 0.013 g/mL) ($P < 0.05$). Additionally, the ROS levels were significantly higher in G5 (HPV, 0.008 g/mL) than in G6 (HPV, 0.013 g/mL) ($P < 0.05$) (Figure 4). No statistically significant differences were found among groups for renal oxidative stress analysis (Figure 5). In the GST parameter there are statistically significant differences between G1 (WT, water) and G2 (HPV, water), and also between G2 (HPV, water) and G5 (HPV, 0.008 g/mL) ($P < 0.05$) (Figure 5).




Figure 2. Histopathological changes induced by HPV16 oncogenes in *wild-type* (WT) mice. Hematoxylin and eosin stain. Ear pavilion lesions: (A) normal skin histology; (B) hyperplasia; (C) dysplasia (red arrow); (D) carcinoma *in situ* (red arrow). Chest skin lesions: (A) normal skin histology; (B) hyperplasia (red arrow); (C) dysplasia; (D) carcinoma *in situ* (red arrow). Scale bar = 25 μ m. Magnification = 250 $\times$

Table 6. Number of animals (%) with histological lesions in the lungs, liver, spleen, and kidney in all experimental groups

Histological organs lesions		G1 WT water	G2 HPV water	G3 WT 0.013 g/mL	G4 HPV 0.006 g/mL	G5 HPV 0.008 g/mL	G6 HPV 0.013 g/mL
Lungs							
Mononucleated inflammation intensity		0(0%)	3(60%)	0(0%)	1(20%)	1(20%)	1(20%)
Atelectasis		0(0%) ¹	5(100%)	2(40%)	1(20%)	1(20%)	4(80%)
Congestion		3(60%)	5(100%)	0(0%)	2(40%)	0(0%)	3(60%)
Hyperaemia		4(80%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
Liver							
Hydropic degeneration		0(0%)	1(20%)	0(0%)	0(0%)	2(40%)	0(0%)
Inflammatory infiltrate	Periportal	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Centrilobular	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)	0(0%)
	Midzonal	0(0%)	5(100%)	3(60%)	3(60%)	3(60%)	1(20%)
Congestion		5(100%)	5(100%)	1(20%)	2(40%)	3(60%)	5(100%)
Spleen							
Diffuse white pulp: hyperplasia		0(0%)	0(0%)	2(40%)	1(20%)	4(80%)	1(20%)
Expansion of the splenic red pulp: congestion		0(0%)	4(80%)	0(0%)	0(0%)	0(0%)	0(0%)
Kidney							
Inflammatory infiltrate		1(20%)	5(100%)	0(0%)	3(60%)	3(60%)	3(60%)
Hydronephrosis		1(20%)	4(80%)	1(20%)	1(20%)	1(20%)	0(0%)
Congestion		5(100%)	5(100%)	5(100%)	3(60%)	5(100%)	5(100%)
Hyperaemia		1(20%)	3(60%)	0(0%)	0(0%)	1(20%)	0(0%)
Vascular ectasia		0(0%)	1(20%)	0(0%)	0(0%)	0(0%)	0(0%)

¹ Significantly different from the G2 ($P < 0.05$). G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL

Discussion

HPV is the most common sexually transmitted infection [39]. There are many different types of HPV, including non-oncogenic types (low-risk HPVs) that can cause warts [40]. Oncogenic types of HPV (high-risk HPVs), such as type 16 and 18, have the potential to initiate pre-malignant lesions that may progress into various types of cancer, including cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers.




Figure 3. Hepatic and splenic changes in HPV16-transgenic mice, hematoxylin, and eosin. Liver: (A) congestion; (B) inflammatory infiltrate (red arrow); (C) hydropic degeneration (red arrow). Magnification = 400 $\times$. Spleen: (A) congestion (red arrow); (B) white pulp: hyperplasia (red arrow). Scale bar = 25 μ m. Magnification = 100 $\times$

This progress occurs when the infection persists by evading immune surveillance [41–43]. Cell transformation is mediated by viral oncoproteins E6, E7 and E5, which interfere with cellular proliferation, differentiation, and survival [44]. The K14-HPV16 transgenic mouse model was developed, in which the human cytokeratin 14 (K14) gene promoter activates all early genes, including E6 and E7, specifically in the basal cells of the keratinized squamous epithelia [8]. Thus, this model shows potential for investigating the pathophysiological mechanisms underlying HPV16-induced carcinogenesis and assessing the effects of various natural compounds and different drugs on the progression of this disease [13, 14, 45, 46]. In this study, we evaluated the chemopreventive effects of *A. citrodora* extract for the first time in a K14-HPV16 transgenic mouse model. Tammar et al. [47] studied the phenolic compound profile of methanolic *A. citrodora* extract and identified nine phenolic compounds, including caffeoylshikimic acid, catechin-gallate, 3,4-Di-caffeoylquinic acid, acteoside, isoacteoside, martynoside, diosmetin, and apigenin. Caffeoylshikimic acid has been found to exhibit antiproliferative activity against various cancer cell lines and promote cancer cell apoptosis [48]. 3,4-Di-caffeoylquinic acid exhibited antioxidant activity [49]. Another antineoplastic agent that has been shown to have such activity was acteoside and isoacteoside [50]. Martynoside has demonstrated chemoprotective effects both *in vivo* and *ex vivo* [51]. Diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic and anti-inflammatory activities [52]. Apigenin has potential antioxidant, anti-inflammatory, and anticancer properties [53]. Our findings showed that there were no mortality or noteworthy alterations in terms of behavioral indicators (such as alertness, restlessness, irritability, and fearfulness), neurological symptoms (including bleeding, convulsions, gait abnormalities, and pain), respiratory function, or gastrointestinal effects (such as stomachache and diarrhea). The humane endpoints were not indicative of animals' sacrifice before the end of the assay. These results indicate that, under the current experimental conditions, the *A. citrodora* extract does not interfere with the well-being of the animals, demonstrating its non-toxic properties. The body weight of WT and HPV mice treated with *A. citrodora* extract was significantly lower than that of the control groups. Negative changes in the animals' body weight are commonly associated with toxicity [54]. Regarding the mean relative weight of internal organs, the HPV groups exhibited the highest weights. This may be related to the inflammatory infiltrate microscopically identified in these groups. *A. citrodora* extract is known to have a protective effect on glucose blood levels in diabetes [55] as evidenced by low levels in mice that consumed the extract. The parameters microhematocrit, albumin, and total proteins showed a tendency to increase in HPV animals that ingested the extract, these increments may be due to animal's dehydration, caused by HPV skin lesions, as described in previous works [15]. *A. citrodora* extract did not significantly alter basal levels of genetic or oxidative damage. However, the concentration of 0.008 g/mL appears to be




Figure 4. Liver oxidative stress. Cu/Zn-SOD (U SOD/mg protein); CAT (U CAT/mg protein); GPx (nmol NADPH reduced/min.mg protein); GR (nmol NADPH reduced/min.mg protein); GST (nmol CDNB conjugated/min.mg protein); GSH (μmol GSH/mg protein); GSSG (μmol GSSG/mg protein); OSI (GSH/GSSG); LPO (μmol MDA/mg protein); ROS (nmol DCF/mg protein); and CO (nmol NADH/min.mg protein). Statistically significant differences in the ROS marker between G2 (HPV, water) and G6 (HPV, 0.013 g/mL), and G5 (HPV, 0.008 g/mL). G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL.

the least harmful and may have a greater protective effect. It is worth noting that the literature mentions the protective effects of *A. triphylla*, a plant from the same family of as *A. citrodora*, against genetic damage induced by cisplatin [56]. The histological examination of the collected organs in, WT mice did not reveal any lesion, while HPV mice exhibited hyperplastic lesions with dysplastic foci and, carcinoma *in situ*. The




Figure 5. Kidney oxidative stress. Cu/Zn-SOD (U SOD/mg protein); CAT (U CAT/mg protein); GPx (nmol NADPH reduced/min.mg protein); GR (nmol NADPH reduced/min.mg protein); GST (nmol CDNB conjugated/min.mg protein); GSH (μmol GSH/mg protein); GSSG (μmol GSSG/mg protein); OSI (GSH/GSSG); LPO (μmol MDA/mg protein); ROS (nmol DCF/mg protein); and CO (nmol NADH/min.mg protein). Statistically significant differences in the GST marker between G1 (WT, water) and G2 (HPV, water). G1 are *wild-type* (WT) mice that drink water; G2 are mice with human papillomavirus (HPV) that drank water; G3 are WT that drank daily an aqueous extract of *Aloysia citrodora* at a concentration of 0.013 g/mL; G4 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.006 g/mL; G5 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.008 g/mL; G6 are mice with HPV that drank daily an aqueous extract of *A. citrodora* at a concentration of 0.013 g/mL.

groups that ingested the *A. citrodora* extract showed a reduction in the most aggressive lesions, such as dysplasia and carcinoma. Lesions were solely identified in the chest from the HPV groups, the G2 (HPV, water) exhibited lesions such as hyperplasia and dysplasia. The severity of these lesions seems to decrease with the administration of *A. citrodora* extract. Although not statistically significant, there was decrease in the severity of liver injuries as the concentration of *A. citrodora* extract increased. A similar trend was

observed in the spleen. The imbalance between antioxidants and oxidants leads to oxidative stress, which favors oxidative agents and results in the excessive production of free radicals, namely ROS, causing biological damage. The ROS are generated through normal metabolic pathways in the hepatic mitochondria and are regulated by antioxidant mechanisms to maintain low levels. Although necessary for normal cellular functions, elevated levels of free radicals can lead to oxidative stress [57]. Upon examining the WT and HPV control groups, it is evident that liver inflammation caused by HPV16 is associated with oxidative stress, similar results were previously observed [58]. To address this issue, it will be necessary to activate the antioxidant system by increasing the levels of enzymes SOD, CAT, and GR. However, even with the activated antioxidant defense system, it is insufficient to fully prevent oxidative stress. Upon examining the WT and HPV groups that consumed the *A. citrodora* extract, we observed a tendency towards decreased liver LPO and increased OSI, indicating a reduction in oxidative stress. This was associated with an increase in antioxidant enzymes SOD, CAT, GR. Notably, there was a significant decrease in ROS levels in HPV mice. At a concentration of 0.013 g/mL, the *A. citrodora* extract effectively reduced ROS levels. In the kidneys, oxidative stress leads to a decrease in OSI and LPO enzymes in the HPV and WT control groups, as well as a decrease in SOD and GR. However, in the groups exposed to *A. citrodora* extract, the decrease in oxidative stress was intensified. The parameters of renal functionality (creatinine) and hepatic functionality (ALT) did not differ between the groups. Therefore, combining these results with the results of oxidative stress, we can say that the consumption of *A. citrodora* does not have a negative impact on hepatic functionality. In this study, we evaluated the impact of an extract prepared through infusion of *A. citrodora*. In future research, it will be crucial to investigate the effects of the fresh plant. Additionally, we suggest isolating the various compounds identified in this plant and conducting individual assessments of their properties in the form of isolated extracts.

Conclusions

In this model, *A. citrodora* decrease the incidence of dysplastic skin lesions caused by HPV16. This suggests that dietary supplementation at concentrations of 0.008 g/mL and 0.013 g/mL has chemopreventive effects. Furthermore, these results show that the tested concentrations of *A. citrodora* were safe and did not induce toxicity under the current experimental conditions. Moving forward, it would be crucial to test concentrations higher than 0.013 g/mL to ascertain if we can achieve more promising outcomes against HPV16 lesions in this strain.

Abbreviations

CAT: catalase

DNA: deoxyribonucleic acid

FPG: formamidopyrimidine DNA glycosylase

GDI: genetic damage index

GR: glutathione reductase

HPV: human papillomavirus

LPO: lipid peroxidation

MDA: malondialdehyde

MS: mass spectrometer

OSI: oxidative stress index

ROS: reactive oxygen species

SOD: superoxide dismutase

WT: *wild-type*

Declarations

Author contributions

BMF: Conceptualization, Investigation, Writing—original draft. AIFR, MJP, MJN, IG, MMSMB, and CV: Writing—review & editing. HV, CVN, JS, MGS, LG, MID, LB, and LF: Investigation, Writing—review & editing. RM and RMGDC: Writing—review & editing, Supervision. PAO: Conceptualization, Writing—review & editing, Supervision.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The experimental work was approved by the animal facility of the University of Trás-os-Montes e Alto Douro (UTAD) with the authorization of the Ethics Committee (approval no. 852-e-CITAB-2020_A_1-e- 122 CITAB-2021) and the Portuguese Veterinary Directorate (approval no. 014139).

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

Beatriz Medeiros-Fonseca has a Ph.D. grant with number [2020.07675.BD] (<https://doi.org/10.54499/2020.07675.BD>); Jéssica Silva has a Ph.D. grant with number [2020.07999.BD] (<https://doi.org/10.54499/2020.07999.BD>); Mónica G. Silva has a Ph.D. grant with number [UI/BD/151320/2021] (<https://doi.org/10.54499/UI/BD/151320/2021>) financed by FCT (Foundation for Science and Technology) through FSE (European Social Fund). This work is supported by National Funds by FCT-Portuguese under projects: CITAB [UID/04033/2020] (<https://doi.org/10.54499/UIDB/04033/2020>); CERNAS [UIDB/00681/2020] (<https://doi.org/10.54499/UIDB/00681/2020>); LEPABE [UIDB/00511/2020] (<https://doi.org/10.54499/UIDB/00511/2020>) and [UIDP/00511/2020] (<https://doi.org/10.54499/UIDP/00511/2020>); ALiCE [LA/P/0045/2020] (<https://doi.org/10.54499/LA/P/0045/2020>); CIMO [UIDB/00690/2020] (<https://doi.org/10.54499/UIDB/00690/2020>) and [UIDP/00690/2020] (<https://doi.org/10.54499/UIDP/00690/2020>); SusTEC, [LA/P/0007/2020] (<https://doi.org/10.54499/LA/P/0007/2020>); by national funds through the FCT/MCTES (PIDDAC). Furthermore, national funding by FCT/P.I., through the institutional scientific employment program contract for Lilian Barros, Maria I. Dias (<https://doi.org/10.54499/CEECINST/00016/2018/CP1505/CT0004>), Luís Félix (<https://doi.org/10.54499/2021.00458.CEECIND/CP1690/CT0001>) contract. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

© The Author(s) 2024.

References

1. Bahramsoltani R, Rostamiasrabadi P, Shahpiri Z, Marques AM, Rahimi R, Farzaei MH. *Aloysia citrodora* Paláu (Lemon verbena): A review of phytochemistry and pharmacology. J Ethnopharmacol. 2018;222: 34–51.

2. Hawary SE, Yousif M, Motaal AA, Hameed LAE. Composition and Bioactivities of the Essential Oil from Leaves of *Lippia citriodora* Kunth Cultivated in Egypt. *J Biol Act Prod from Nat*. 2011;1:112–9.
3. Pascual ME, Slowing K, Carretero E, Sánchez Mata D, Villar A. *Lippia*: traditional uses, chemistry and pharmacology: a review. *J Ethnopharmacol*. 2001;76:201–14.
4. Baratta MT, Dorman HJD, Deans SG, Figueiredo AC, Barroso JG, Ruberto G. Antimicrobial and antioxidant properties of some commercial essential oils. *Flavour Fragrance J*. 1998;13:235–44.
5. Salama Y, Jaradat N, Hattori K, Heissig B. Aloysia Citroedora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling. *Int J Mol Sci*. 2021;22:8151.
6. Almeida HHS, Crugeira PJJ, Amaral JS, Rodrigues AE, Barreiro MF. Disclosing the potential of *Cupressus leylandii* A.B. Jacks & Dallim, *Eucalyptus globulus* Labill., *Aloysia citrodora* Paláu, and *Melissa officinalis* L. hydrosols as eco-friendly antimicrobial agents. *Nat Prod Bioprospect*. 2024;14:1.
7. Al-Maharik N, Salama Y, Al-Hajj N, Jaradat N, Jobran NT, Warad I, et al. Chemical composition, anticancer, antimicrobial activity of *Aloysia citriodora* Palau essential oils from four different locations in Palestine. *BMC Complement Med Ther*. 2024;24:94.
8. Arbeit JM, Münger K, Howley PM, Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. *J Virol*. 1994;68:4358–68.
9. Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Ghezzi F, et al. HPV persistence after cervical surgical excision of high-grade cervical lesions. *Cancer Cytopathol*. 2024;132:268–9.
10. Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Giannini A, et al.; Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV); The Investigators of the Italian HPV study group (iHPV study group). Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. *Eur J Cancer Prev*. 2023;32:525–32.
11. Bogani G, Sopracordevole F, Ciavattini A, Ghelardi A, Vizza E, Vercellini P, et al. HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of vaccination. *Tumori*. 2024;110:139–45.
12. Bogani G, Raspagliesi F, Sopracordevole F, Ciavattini A, Ghelardi A, Simoncini T, et al. Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. *Vaccines (Basel)*. 2020;8:717.
13. Medeiros-Fonseca B, Mestre VF, Colaço B, Pires MJ, Martins T, Gil da Costa RM, et al. *Laurus nobilis* (laurel) aqueous leaf extract's toxicological and anti-tumor activities in HPV16-transgenic mice. *Food Funct*. 2018;9:4419–28.
14. Santos C, Ferreira P, Sousa H, Ribeiro J, Bastos MM, Neto T, et al. Ptaquiloside from bracken (*Pteridium* spp.) inhibits tumour-infiltrating CD8⁺ T cells in HPV-16 transgenic mice. *Food Chem Toxicol*. 2016;97:277–85.
15. Gil da Costa RM, Aragão S, Moutinho M, Alvarado A, Carmo D, Casaca F, et al. HPV16 induces a wasting syndrome in transgenic mice: Amelioration by dietary polyphenols via NF-κB inhibition. *Life Sci*. 2017;169:11–9.
16. Bessada SMF, Barreira JCM, Barros L, Ferreira ICFR, Oliveira MBPP. Phenolic profile and antioxidant activity of *Coleostephus myconis* (L.) Rchb.f.: An underexploited and highly disseminated species. *Ind Crops Prod*. 2016;89:45–51.
17. Edwards DA. Early androgen stimulation and aggressive behavior in male and female mice. *Physiol Behav*. 1969;4:333–8.
18. Paiva I, Gil da Costa RM, Ribeiro J, Sousa H, Bastos MM, Faustino-Rocha A, et al. MicroRNA-21 expression and susceptibility to HPV-induced carcinogenesis - role of microenvironment in K14-HPV16 mice model. *Life Sci*. 2015;128:8–14.
19. Hubrecht RC, Carter E. The 3Rs and Humane Experimental Technique: Implementing Change. *Animals (Basel)*. 2019;9:754.

20. Silva-Reis R, Faustino-Rocha AI, Gonçalves M, Castro Ribeiro C, Ferreira T, Ribeiro-Silva C, et al. Refinement of Animal Model of Colorectal Carcinogenesis Through the Definition of Novel Humane Endpoints. *Animals (Basel)*. 2021;11:985.
21. Oliveira M, Nascimento-Gonçalves E, Silva J, Oliveira PA, Ferreira R, Antunes L, et al. Implementation of Humane Endpoints in a Urinary Bladder Carcinogenesis Study in Rats. *In Vivo*. 2017;31:1073–80.
22. Forbes D, Blom H, Kostomitsopoulos N, Moore G, Perretta G. *Euroguide: On the Accommodation and Care of Animals Used for Experimental and Other Scientific Purposes*. London: Royal Society of Medicine Press Ltd; 2007.
23. Shaposhnikov S, Azqueta A, Henriksson S, Meier S, Gaivão I, Huskisson NH, et al. Twelve-gel slide format optimised for comet assay and fluorescent in situ hybridisation. *Toxicol Lett*. 2010;195:31–4.
24. Guilherme S, Santos MA, Gaivão I, Pacheco M. DNA and chromosomal damage induced in fish (*Anguilla anguilla* L.) by aminomethylphosphonic acid (AMPA)--the major environmental breakdown product of glyphosate. *Environ Sci Pollut Res Int*. 2014;21:8730–9.
25. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. *Mol Biotechnol*. 2004;26:249–61.
26. Mega C, Vala H, Rodrigues-Santos P, Oliveira J, Teixeira F, Fernandes R, et al. Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. *Diabetol Metab Syndr*. 2014;6: 42.
27. Shackelford C, Long G, Wolf J, Okerberg C, Herbert R. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. *Toxicol Pathol*. 2002;30:93–6.
28. Mekuria AN, Tura AK, Hagos B, Sisay M, Abdela J, Mishore KM, et al. Anti-Cancer Effects of Lycopene in Animal Models of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. *Front Pharmacol*. 2020;11:1306.
29. Taib M, Bouyazza L, Lyoussi B. Acorn Oil: Chemistry and Functionality. *J Food Qual*. 2020;2020: e8898370.
30. Durak I, Yurtarlan Z, Canbolat O, Akyol Ö. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. *Clinica Chimica Acta*. 1993;214:103–4.
31. Aebi H. Catalase in vitro. *Methods Enzymol*. 1984;105:121–6.
32. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med*. 1967;70:158–69.
33. Carlberg I, Mannervik B. Glutathione reductase. *Methods Enzymol*. 1985;113:484–90.
34. Vessey DA, Boyer TD. Differential activation and inhibition of different forms of rat liver glutathione S-transferase by the herbicides 2,4-dichlorophenoxyacetate (2,4-D) and 2,4,5-trichlorophenoxyacetate (2,4,5-T). *Toxicol Appl Pharmacol*. 1984;73:492–9.
35. Gartaganis SP, Patsoukis NE, Nikolopoulos DK, Georgiou CD. Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome. *Eye (Lond)*. 2007;21:1406–11.
36. Schieber M, Chandel Navdeep S. ROS Function in Redox Signaling and Oxidative Stress. *Curr Biology*. 2014;24:R453–62.
37. Faridi R, Zahra A, Khan K, Idrees M. Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. *Viol J*. 2011;8:269.
38. Mesquita CS, Oliveira R, Bento F, Geraldo D, Rodrigues JV, Marcos JC. Simplified 2,4-dinitrophenylhydrazine spectrophotometric assay for quantification of carbonyls in oxidized proteins. *Anal Biochem*. 2014;458:69–71.
39. Brianti P, De Flammis E, Mercuri SR. Review of HPV-related diseases and cancers. *New Microbiol*. 2017;40:80–5.

40. Cheah PL, Looi LM. Biology and pathological associations of the human papillomaviruses: a review. *Malays J Pathol.* 1998;20:1–10.
41. Aimagambetova G, Azizan A. Epidemiology of HPV Infection and HPV-Related Cancers in Kazakhstan: a Review. *Asian Pac J Cancer Prev.* 2018;19:1175–80.
42. Spence T, Bruce J, Yip KW, Liu FF. HPV Associated Head and Neck Cancer. *Cancers (Basel).* 2016;8:75.
43. Santos C, Vilanova M, Medeiros R, Gil da Costa RM. HPV-transgenic mouse models: Tools for studying the cancer-associated immune response. *Virus Res.* 2017;235:49–57.
44. Estêvão D, Costa NR, Gil da Costa RM, Medeiros R. Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy. *Biochim Biophys Acta Gene Regul Mech.* 2019;1862: 153–62.
45. Ferreira T, Nascimento-Gonçalves E, Macedo S, Borges I, Gama A, M Gil da Costa R, et al. Toxicological and anti-tumor effects of a linden extract (*Tilia platyphyllos* Scop.) in a HPV16-transgenic mouse model. *Food Funct.* 2021;12:4005–14.
46. Santos S, Ferreira T, Almeida J, Pires MJ, Colaço A, Lemos S, et al. Dietary Supplementation with the Red Seaweed *Porphyra umbilicalis* Protects against DNA Damage and Pre-Malignant Dysplastic Skin Lesions in HPV-Transgenic Mice. *Mar Drugs.* 2019;17:615.
47. Tammar S, Salem N, Aidi Wannes W, Limam H, Bourgou S, Fares N, et al. Chemometric Profiling and Bioactivity of Verbena (*Aloysia citrodora*) Methanolic Extract from Four Localities in Tunisia. *Foods.* 2021;10:2912.
48. 5-CAFFEYOYLSHIKIMIC ACID [Internet]. Bethesda (MD): National Center for Advancing Translational Sciences; [cited 2023 Oct 11]. Available from: <https://drugs.ncats.io/drug/5U399BD0RZ>
49. Ooi KL, Muhammad TS, Tan ML, Sulaiman SF. Cytotoxic, apoptotic and anti- α -glucosidase activities of 3,4-di-O-caffeoyl quinic acid, an antioxidant isolated from the polyphenolic-rich extract of *Elephantopus mollis* Kunth. *J Ethnopharmacol.* 2011;135:685–95.
50. Pettit GR, Numata A, Takemura T, Ode RH, Narula AS, Schmidt JM, et al. Antineoplastic agents, 107. Isolation of acteoside and isoacteoside from *Castilleja linariaefolia*. *J Nat Prod.* 1990;53:456–8.
51. Hong M, Chen D, Hong Z, Tang K, Yao Y, Chen L, et al. Ex vivo and in vivo chemoprotective activity and potential mechanism of Martynoside against 5-fluorouracil-induced bone marrow cytotoxicity. *Biomed Pharmacother.* 2021;138:111501.
52. Patel K, Gadewar M, Tahilyani V, Patel DK. A review on pharmacological and analytical aspects of diosmetin: a concise report. *Chin J Integr Med.* 2013;19:792–800.
53. Madunić J, Madunić IV, Gajski G, Popić J, Garaj-Vrhovac V. Apigenin: A dietary flavonoid with diverse anticancer properties. *Cancer Lett.* 2018;413:11–22.
54. Silva SLD, Nascimento AAD, Ribeiro EFB, Ribeiro RB, Alves CM, Santos AMD, et al. Avaliação da toxicidade aguda pré-clínica do extrato metanólico das cascas do caule de *Parahancornia amapa* (Apocynaceae). *Acta Amaz.* 2016;46:73–80. Portuguese.
55. Lee YS, Yang WK, Kim HY, Min B, Caturla N, Jones J, et al. Metabolaid® Combination of Lemon Verbena and Hibiscus Flower Extract Prevents High-Fat Diet-Induced Obesity through AMP-Activated Protein Kinase Activation. *Nutrients.* 2018;10:1204.
56. Zamorano-Ponce E, Fernández J, Vargas G, Rivera P, Carballo MA. Protective activity of cedron (*Aloysia triphylla*) infusion over genetic damage induced by cisplatin evaluated by the comet assay technique. *Toxicol Lett.* 2004;152:85–90.
57. Zehra M, Curry JC, Pillai SS, Lakhani HV, Edwards CE, Sodhi K. Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis. *Int J Mol Sci.* 2020;21: 4737.
58. Ferreira T, Campos S, Silva MG, Ribeiro R, Santos S, Almeida J, et al. The Cyclooxygenase-2 Inhibitor Parecoxib Prevents Epidermal Dysplasia in HPV16-Transgenic Mice: Efficacy and Safety Observations. *Int J Mol Sci.* 2019;20:3902.